RT Journal Article
SR Electronic
T1 Somatostatin Receptor–Targeted Radiopeptide Therapy with <sup>90</sup>Y-DOTATOC and <sup>177</sup>Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 171
OP 176
DO 10.2967/jnumed.114.147256
VO 56
IS 2
A1 Marincek, Nicolas
A1 Radojewski, Piotr
A1 Dumont, Rebecca A.
A1 Brunner, Philippe
A1 Müller-Brand, Jan
A1 Maecke, Helmut R.
A1 Briel, Matthias
A1 Walter, Martin A.
YR 2015
UL http://jnm.snmjournals.org/content/56/2/171.abstract
AB Meningiomas express members of the somatostatin receptor family. The present study assessed the long-term benefits and harm of somatostatin-based radiopeptide therapy in meningioma patients. Methods: Patients with progressive unresectable meningioma were treated with 90Y-DOTATOC and 177Lu-DOTATOC until tumor progression or permanent toxicity occurred. Multivariable Cox regression analyses were used to study predictors of survival. Results: Overall, 74 treatment cycles were performed on 34 patients. Stable disease was achieved in 23 patients. Severe hematotoxicity occurred in 3 patients, and severe renal toxicity in 1 patient. Mean survival was 8.6 y from the time of recruitment. Stable disease after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001–0.35; n = 34; P = 0.01) and high tumor uptake (hazard ratio, 0.046 vs. intermediate or low tumor uptake; 95% confidence interval, 0.004–0.63; n = 34; P = 0.019) were associated with longer survival. Conclusion: 90Y-DOTATOC and 177Lu-DOTATOC are promising tools for treating progressive unresectable meningioma, especially in cases of high tracer uptake in the tumor.